No Data
No Data
ZeJing Pharmaceutical's 2024 interim report
Summary of Zejing Pharmaceuticals' semi-annual report for 2024
Pharmaceutical company Zejing (688266.SH) released its performance for the first half of the year, with a net loss of 66.5361 million yuan.
Zejing Pharmaceuticals (688266.SH) has released its 2024 interim report, with a revenue of 2...
Zejing Pharmaceuticals (688266.SH): a net loss of 66.536 million yuan in the first half of the year, a decrease in losses compared to the same period last year.
On August 23, Zijing Pharmaceutical (688266.SH) released its semi-annual report, with revenue of 0.24 billion yuan, a year-on-year growth of 9.44%. The net loss was 66.536 million yuan, a decrease in losses compared to the previous year, and a non-GAAP net loss of 72.37 million yuan, a decrease in losses compared to the previous year. The basic earnings per share was -0.25 yuan.
Haitong Int'l: Immune therapy has a broad market space, and the clinical value of TCE dual-antibodies is prominent.
With the development and maturity of TCE dual antibody technology, more domestic enterprises will choose to layout TCE dual antibody in order to enter the race track of solid tumors and self-immunity areas. TCE dual antibody has the potential to become the next investment trend in the field of immunotherapy.
Zelgen Biopharma's Thyroid Cancer Drug Gets Clinical, Pharmaceutical Registration Verification
No Data